4.9 (207) In stock
Mutations in BRCA genes are linked to the early onset of breast and ovarian cancers. But the effect of most mutations is unclear. Now new research can distinguish harmless from dangerous mutations.
Genome editing and cancer: How far has research moved forward on CRISPR/Cas9? - ScienceDirect
Frontiers Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy
BRCA mutations can be deadly or harmless. Now CRISPR can tell the difference - Genetic Literacy Project
John Martin on LinkedIn: CRISPR 'barcodes' map mammalian development in exquisite detail
Ovarian cancer – information, recherche et analyse – The Conversation France, page 1
Exploring nano-enabled CRISPR-Cas-powered strategies for efficient diagnostics and treatment of infectious diseases
CRISPR Clinical Trials: A 2023 Update - Innovative Genomics Institute (IGI)
BRCA2 – News, Research and Analysis – The Conversation – page 1
CRISPR/Cas genome editing in triple negative breast cancer: Current situation and future directions - ScienceDirect
Genes, Free Full-Text
